GLP-1 coverage in Minnesota

Coverage beats every cash price on this site. In Minnesota the question is whether you can get it — and the answer moved in the last year.

Minnesota Medicaid covers GLP-1s for obesity treatment.

Minnesota is among the states KFF lists as covering GLP-1s for obesity, and like Virginia it has featured on these lists consistently rather than intermittently. Everything below is sourced — we are not going to tell you what a Minnesota clinic charges, because every provider we track is 50-state telehealth and prices the same wherever you live. What actually differs by state is coverage, and that is what this page is about.

What it is worth in money

Medicaid enrollees generally pay little or nothing for covered prescriptions. Against our cheapest verified cash programme at $86 a month, coverage is worth around $1,000 a year — more than any discount, membership trick or annual plan on this entire site.

Why Minnesota is different

Minnesota sits in the Midwest, which carries the highest regional adult obesity prevalence in the country at 35.9% — higher than the South, which surprises most people. A covering state in the highest-prevalence region reaches proportionally more people than the same policy would elsewhere.

If you are on Medicaid in Minnesota

What to do in Minnesota: Ask about prior authorisation requirements up front. Coverage existing and coverage being straightforward to obtain are different things.

Coverage for type 2 diabetes, cardiovascular disease and sleep apnea is mandatory everywhere, so a refusal framed around weight loss is not the end of it — and on Medicare, the $50 programme starts 1 July 2026 regardless of which state you are in.

Paying cash in Minnesota

Providers are licensed across all 50 states and charge the same here as anywhere, so there is no local price to hunt for — the cheapest verified all-in rates are SuperHealthy Rx at $85 for semaglutide and Trimi at $125 for tirzepatide. Full tables in the cheapest tirzepatide. If you buy compounded, check the pharmacy licence with the Minnesota Board of Pharmacy,

Minnesota: common questions

Does Minnesota cover both semaglutide and tirzepatide?

KFF tracks coverage of GLP-1s for obesity at programme level rather than drug by drug. Ask about the specific medication by name — that distinction has caught people out in several states.

Is the Midwest really the highest-prevalence region?

Yes — CDC’s 2024 data puts the Midwest at 35.9% against the South at 34.5%. The common assumption that the South leads is out of date.

Sources: KFF, “Medicaid Coverage of and Spending on GLP-1s”, 16 January 2026; CDC Adult Obesity Prevalence Maps, 2024 data, published 3 December 2025. Verified 2026-09-18. Coverage positions change mid-year — confirm yours with your plan. Not medical, legal or benefits advice.